98%
921
2 minutes
20
Background: Current challenges in bone grafting revolve around the limited availability of autografts and the complications associated with their use. Promising alternatives include osteoinductive substances stimulating stem cells to mature into bone-forming osteoblasts. However, existing products lack optimal characteristics of a bone graft. The study aimed to evaluate the impact of L-arginine treatment on hydroxyapatite (HA) derived from ovine bone and compare its surface and mechanical properties to that of the commercially available xenograft-Bio-Oss.
Materials And Methods: The research was structured as an investigation, wherein HA was formulated from ovine bone. The sintering process involved heating it to 360°C for 3 h and adding the amino acid L-arginine. Different tests were done which included scanning electron microscopy (SEM), X-ray diffractometry, Fourier-transform infrared spectroscopy (FTIR), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The goal was to compare these results with a commercially available bone graft called BioOss, especially regarding their physical and chemical characteristics. Data were analyzed in SPSS software using one way ANOVA test, significant level at 0.05.
Results: A bone graft made of HA and L-arginine displayed a complex and interconnected pore structure, indicating that the sintering process had a significant impact. SEM confirmed this. FTIR analysis identified peaks at 650-700 cm and 1000-1100 cm, confirming the presence of HA and L-arginine. X-ray Diffraction assessments also confirmed the existence of both substances in the sintered specimens, supporting their suitability for various biomedical applications.
Conclusion: The study presents a novel approach, deproteinizing a bone graft followed by sintering at 360°C with L-arginine. Physicochemical analyses confirmed desired mechanical attributes and surface characteristics. Further investigations are needed to evaluate cellular adherence, immunological response, and osteogenesis in relevant animal models.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12155389 | PMC |
http://dx.doi.org/10.4103/drj.drj_263_24 | DOI Listing |
J Pediatric Infect Dis Soc
September 2025
Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, Greece.
Background: Critically ill pediatric patients admitted to the PICU are highly vulnerable to infections, including invasive fungal diseases and antifungal agents are frequently prescribed. Little is known about antifungal usage in PICUs across Europe.
Methods: A multinational 3-month weekly point-prevalence study for measuring antifungal drug use was organized.
Front Immunol
September 2025
Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
NSG-SGM3 humanized mouse models are well-suited for studying human immune physiology but are technically challenging and expensive. We previously characterized a simplified NSG-SGM3 mouse, engrafted with human donor CD34 hematopoietic stem cells without receiving prior bone marrow ablation or human secondary lymphoid tissue implantation, that still retains human mast cell- and basophil-dependent passive anaphylaxis responses. Its capacities for human antibody production and human B cell maturation, however, remain unknown.
View Article and Find Full Text PDFJ Exp Pharmacol
September 2025
Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Purpose: Acute graft-versus-host disease (aGVHD) is a significant cause of death in recipients of allogeneic hematopoietic stem cell transplantation. In this type of graft, the intestine is particularly affected, with the loss of intestinal barrier integrity playing a key role in its onset. In this scenario, the aim of the present research was to evaluate defibrotide, a heparin-like compound, marked for severe veno-occlusive disease, as an innovative therapeutic approach for restoring intestinal barrier integrity using an in vitro model and analyzing aGVHD patients' sera and clinical data.
View Article and Find Full Text PDFBlood Cell Ther
August 2025
Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.
[This corrects the article DOI: 10.31547/bct-2024-020.].
View Article and Find Full Text PDFBlood Cell Ther
August 2025
Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, Canada.
Introduction: The impact of race on outcomes of allogeneic hematopoietic cell transplants (HCT) has long been a field of research. The Center for International Blood and Marrow Transplant Research (CIBMTR) studies have shown worse survival for Black and Hispanic patients within the first year after HCT, but rates evened out for one-year survivors. From our personal experience, we hypothesize that the outcomes of South Asians (age ≥ 45 years) receiving myeloablative conditioning (MAC) are also worse compared to other races.
View Article and Find Full Text PDF